463 related articles for article (PubMed ID: 25799277)
1. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
[TBL] [Abstract][Full Text] [Related]
2. Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
Wei YF; Chu CY; Chang CC; Lin SH; Su WC; Tseng YL; Lin CC; Yen YT
Lung Cancer; 2018 Nov; 125():35-42. PubMed ID: 30429036
[TBL] [Abstract][Full Text] [Related]
3. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma.
Yokoyama S; Miyoshi H; Nishi T; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Kakuma T; Ohshima K
Ann Thorac Surg; 2016 Apr; 101(4):1361-9. PubMed ID: 26794891
[TBL] [Abstract][Full Text] [Related]
5. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
Guleria P; Husain N; Shukla S; Kumar S; Parshad R; Jain D
Ann Diagn Pathol; 2018 Jun; 34():135-141. PubMed ID: 29661720
[TBL] [Abstract][Full Text] [Related]
7. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
[TBL] [Abstract][Full Text] [Related]
8. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
Berardi R; Goteri G; Brunelli A; Pagliaretta S; Paolucci V; Caramanti M; Rinaldi S; Refai M; Pompili C; Morgese F; Torniai M; Marcantognini G; Ricci G; Mazzanti P; Onofri A; Bianchi F; Sabbatini A; Cascinu S
Expert Opin Ther Targets; 2020 Sep; 24(9):937-943. PubMed ID: 32662701
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis.
Chen HF; Wu LX; Li XF; Zhu YC; Pan WW; Wang WX; Xu CW; Huang JH; Wu MH; Du KQ
Tumori; 2020 Aug; 106(4):306-311. PubMed ID: 32366210
[TBL] [Abstract][Full Text] [Related]
11. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
Weissferdt A; Fujimoto J; Kalhor N; Rodriguez J; Bassett R; Wistuba II; Moran CA
Mod Pathol; 2017 Jun; 30(6):826-833. PubMed ID: 28281549
[TBL] [Abstract][Full Text] [Related]
12. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
Kuo TT; Chan JK
Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
[TBL] [Abstract][Full Text] [Related]
13. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
14. Steroid receptor expression in thymomas and thymic carcinomas.
Mimae T; Tsuta K; Takahashi F; Yoshida A; Kondo T; Murakami Y; Okada M; Takeuchi M; Asamura H; Tsuda H
Cancer; 2011 Oct; 117(19):4396-405. PubMed ID: 21437890
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
Dorfman DM; Shahsafaei A; Miyauchi A
Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.
Hakiri S; Fukui T; Mori S; Kawaguchi K; Nakamura S; Ozeki N; Kato T; Goto M; Yatabe Y; Yokoi K
Ann Thorac Surg; 2019 Feb; 107(2):418-424. PubMed ID: 30312607
[TBL] [Abstract][Full Text] [Related]
17. Expression of proteasome subunit β5t in thymic epithelial tumors.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
[TBL] [Abstract][Full Text] [Related]
18. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
[TBL] [Abstract][Full Text] [Related]
19. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
[TBL] [Abstract][Full Text] [Related]
20. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors.
Kim DJ; Yang WI; Kim SH; Park IK; Chung KY
Eur J Cardiothorac Surg; 2005 Oct; 28(4):611-6. PubMed ID: 16125946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]